Recon: States sue to stop cuts to NIH research funds; AbbVie nabs FDA approval for novel antibiotic

• 22 states sue to block Trump administration cuts to NIH research payments (STAT)
• Senators ask FDA to dig into 'misleading' Super Bowl ad from Hims (Endpoints)
• AbbVie wins FDA approval for new antibiotic to treat complex intra-abdominal infections (Endpoints)
• Q4 earnings updates; Biogen details revised research strategy; RFK Jr. advances out of Senate committee; and more (Endpoints)
• TB, malaria, newborn health services must restart, says USAID memo (Reuters)

• Post-Hoc: China tensions both help and hurt Illumina (Endpoints)
• Exclusive: Germany's Merck n talks to buy US biotech firm Springworks, sources say (Reuters)
• Indonesia launches $183 million free health screening to prevent early deaths (Reuters)
• India's Adani ties up with US-based Mayo Clinic for affordable health campuses (Reuters)
• China's health regulator defends quality of local generic drugs (Reuters)
• Post-Market Surveillance: The Rock On Which UK’s Global Regulation Ambitions Will Be Built (MedTech Insight)
• EU Clarifies AI System Definition, Including Specific Medical Technologies (MedTech Insight)

• The life sciences industry needs a new approach (STAT)
• Amid shakeup in U.S. science, researchers express alarm over integrity of key genetic databases (STAT)
• Boehringer Ingelheim touts success in second Phase 3 lung fibrosis trial (Endpoints)
• Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma (Endpoints)
• Roivant discontinues lung disease drug; Bio-Thera, Intas make biosimilar deal (Endpoints)
• Pliant pauses Phase 2b lung fibrosis study after safety board recommendation, shares plummet (Endpoints)
• Sanofi, AstraZeneca back Teva's call to rehear case on patent listings (Endpoints)
• Sionna inks $191M IPO for cystic fibrosis pipeline as Aardvark eyes $89M for its own listing (Endpoints)
• Incyte forecasts downbeat annual sales of skin disease drug, shares fall (Reuters)

• New Teladoc, same acquisition strategy (STAT)
• Two biotechs say they’re using AI to conjure drugs from scratch. Their documents suggest otherwise (STAT)
• FDA posts early alert about BD device linked to 30 injuries, 4 deaths (MedTech Dive)
• M&A and a separation take center stage in latest earnings season (MedTech Dive)
• Why health systems should be ‘clear-eyed’ about business goals for AI tools (MedTech Dive)

• Here’s how big a hit some universities may take if NIH slashes support for indirect research costs (STAT)
• The FDA’s misguided thinking on antibiotics (STAT)
• Indirect research costs are complicated, wonky — and crucial to science (STAT)
• A check-in on health insurers’ medical costs, and more babies are being born (STAT)
• Major FDA staff cuts would slow drug reviews, experts say (Endpoints)
• Health clinics grapple with US funding squeeze (Reuters)